Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, S. Korean Hospital Ink Biomarker Deal

NEW YORK (GenomeWeb News) – Agilent Technologies and Seoul National University Hospital in South Korea are collaborating to develop and verify biomarkers for use in developing drugs, they announced Wednesday.

Drugs to be developed as part of the deal include narcotics and immune suppressants.

Agilent is supplying its 6460 Triple Quadrupole LC/MS system, as well as support services and application expertise to the work. The hospital will create and maintain "an optimal environment for new biomarkers to be identified and tested vigorously," the partners said.

Financial and other terms were not disclosed.

"Through this collaboration, we hope to establish [a] more effective and varied verifications system for the medical and life sciences industries," Rod Minett, general manager of Life Sciences, South Korea and the South Asia-Pacific region, said in a statement.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.